公開中のRFP
RFP Product Development Platform 2025-002NEW!
The GHIT Fund announces the Request for Proposals (RFP) for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects should be no more than two years in duration and may focus on R&D activities in the development stages as illustrated in https://www.ghitfund.org/applyforfunding/opportunities, including:
- Lead optimization
- Preclinical Development (in-vivo studies, formulation development, chemistry and process validation)
- Clinical Development (Phase 1, 2, and 3 studies, manufacturing scale-up)
- Parallel or concurrent development of multiple interventions (e.g., development of new drugs alongside improved diagnostic tools for disease control, advancing multiple promising drug candidates concurrently)
- Activities to support licensure and WHO prequalification
Interested applicants can find detailed information on the RFP and the Intent to Apply form below.
(The schedule is subject to change due to unforeseen circumstances.)
RFP and Intent to Apply
Key RFP Milestone Dates
RFP Release June 12, 2025
Intent to Apply No later than 10:00 am JST on July 9, 2025
*Applicants are encouraged to submit the ITA well in advance of the full proposal submission deadline shown below to secure sufficient time to prepare full proposal.
Submit via Editorial Manager® for PD&HTLP
Platform (https://www.editorialmanager.com/ghitfund/ )
Full Proposal Due No later than 10:00 am JST on August 7, 2025
Submit via Editorial Manager® for PD&HTLP
Platform (https://www.editorialmanager.com/ghitfund/ )
Full proposal templates
*Only eligible applicants will be invited to submit the full proposal and will receive an instruction to access the proposal templates by email.
Proposals Evaluation and Interview Processes August 2025 - February 2026
Notification of Results February 2026
Investment Agreement Fully Executed (Awarded Proposals) March 2026